FRONT-BRAF:BRAFV600E突变转移性NSCLC一线免疫±化疗对比BRAF+MEK抑制剂的回顾性队列研究
FRONT-BRAF多中心回顾性队列纳入284例未经治的IV期BRAFV600E突变NSCLC患者,比较一线ICI±化疗与BRAF+MEK抑制剂的疗效。亚组分析显示吸烟史、PD-L1≥1%、年龄≥70岁、TP53共突变及无脑转移者获益更明显,结果仍需前瞻性研究验证。
要点
- 吸烟史、PD-L1≥1%、≥70岁、TP53共突变、无脑转移者ICI±化疗获益更显著。
- BRAF+MEK抑制剂一线或后线给药的不良事件频率相似;结论仍属探索性。
核心结论
- 在BRAFV600E突变转移性NSCLC中,一线ICI±化疗与较BRAF+MEK抑制剂改善总生存相关,尤其在特定亚组中。
- 该结果提示潜在临床相关性,但仍属探索性,需前瞻性研究确认。
研究设计与样本
- 多中心回顾性队列研究,纳入美国、意大利、法国、巴西共17个中心的284例患者。
- 纳入标准为年龄≥18岁、IV期、未经治、BRAFV600E突变NSCLC、ECOG PS 0-3,2015年1月2日至2024年7月11日启动一线治疗。
- 一线方案为ICI±铂类化疗(PD-1或PD-L1抑制剂)或BRAF+MEK抑制剂(达拉非尼+曲美替尼或恩考芬尼+比美替尼)。
- 主要终点为一线ICI±化疗对比BRAF+MEK抑制剂的总生存。
主要发现
- 284例中88例(31%)接受ICI±化疗,196例(69%)接受BRAF+MEK抑制剂;中位年龄68岁(IQR 61-74),女性148例(52%)。
- BRAF+MEK抑制剂一线或后线(ICI±化疗后)给药时,任何级别及≥3级不良事件频率相似。
临床怎么用
- 对BRAFV600E突变转移性NSCLC一线治疗选择,可将ICI±化疗作为优先考虑之一,尤其存在吸烟史、PD-L1≥1%、年龄≥70岁、TP53共突变或无脑转移时。
- BRAF+MEK抑制剂仍为可选方案,且一线或后线给药不良事件频率相似。
- 治疗决策需结合PD-L1表达、共突变、脑转移状态及体能状态个体化制定。
局限性
- 回顾性设计,存在选择偏倚,两组基线特征(吸烟史、PD-L1表达)不平衡。
- 结果属探索性,需前瞻性研究确认。
- 样本量有限(284例),亚组分析解读需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with BRAFV600E (ie, Val600Glu)-mutated non-small-cell lung cancer (NSCLC) can be treated with BRAF and mitogen-activated protein kinase (MEK) inhibitors, or with immune checkpoint inhibitors (ICIs) with or without chemotherapy. We aimed to investigate which initial systemic treatment should be prioritised in this population. METHODS: In this retrospective cohort study conducted across 17 centres in the USA, Italy, France, and Brazil, clinicopathological data were collected from participants aged 18 years and older with stage IV, treatment-naive, metastatic BRAFV600E-mutated NSCLC and with an Eastern Cooperative Oncology Group performance status of 0-3, who started first-line treatment with ICIs with or without chemotherapy (PD-1 or PD-L1 inhibitors with or without platinum-based chemotherapy) or BRAF and MEK inhibitors (dabrafenib and trametinib or encorafenib and binimetinib) between Jan 2, 2015, and July 11, 2024. The primary endpoint was overall survival with first-line ICIs with or without chemotherapy versus with BRAF and MEK inhibitors. FINDINGS: 284 participants were identified for this study, of whom 88 (31%) received ICIs with or without chemotherapy and 196 (69%) received BRAF and MEK inhibitors. The median age of participants was 68 years (IQR 61-74), and 148 (52%) participants were female and 136 (48%) male. Participants in the ICIs with or without chemotherapy group had a higher history of smoking (73 [83%] vs 118 [60%]; p=0·0002) and a higher PD-L1 expression (≥50% in 58 [66%] vs 76 [39%], 1-49% in 16 [18%] vs 67 [34%], and <1% in eight [9%] vs 31 [16%]; p=0·0003) than those in the BRAF and MEK inhibitor group. At a median follow-up time of 45·0 months (95% CI 39·0-55·7), ICIs with or without chemotherapy were associated with improved median overall survival compared with BRAF and MEK inhibitors (40·9 months [95% CI 33·3-not reached] vs 25·2 months [19·9-31·1]; hazard ratio [HR] 0·69 [0·49-0·98], p=0·039). In subgroup analyses, ICIs with or without chemotherapy, compared with BRAF and MEK inhibitors, were associated with longer median overall survival in participants with a history of smoking (HR 0·60 [0·40-0·90], p=0·013), with a PD-L1 tumour proportion score of ≥1% or higher (HR 0·66 [0·45-0·98], p=0·039), aged 70 years or older (HR 0·54 [0·31-0·94], p=0·029), with TP53 co-mutations (HR 0·46 [0·27-0·79], p=0·0048), and without brain metastases (HR 0·66 [0·45-0·99], p=0·045). With BRAF and MEK inhibitors, frequencies of adverse events of any grade and of grade 3 and higher were similar whether administered as first-line therapy or as second-line therapy following ICIs with or without chemotherapy. INTERPRETATION: First-line ICIs with or without chemotherapy were associated with improved overall survival compared with BRAF and MEK inhibitors in participants with metastatic BRAFV600E-mutated NSCLC, particularly among specific subpopulations. These findings, although suggesting potential clinical relevance, remain exploratory and require confirmation from prospective studies. FUNDING: NextGenerationEU.
引用
- Di Federico A, Wang K, Chen MF, et al. First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study. Lancet Oncol. 2025. PMID: 41038185. doi:10.1016/S1470-2045(25)00409-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。